anonymous
Guest
anonymous
Guest
Does it make sense for Elanco to sell their companion vaccine line in order to pay down their large debt load? Backorders, eroding market share, and not enough incentives for hospitals to switch seem like reasons to not keep at this point. A company like Dechra could buy that business. Curious on your thoughts.